Figure 2
From: Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β
MiR-26a-5p expression levels in INF-β treated MS patient leukocytes. The expression of mir-26a-5p was studied in the peripheral blood from 40 IFN-β treated responder RRMS patients and from 10 IFN-β treated non-responder patients, at starting, at 3 and 6 months IFN-β treatment by microRNA assay-based quantitative RT-PCR following the 2-ΔΔCT method. RNU6B was utilized for an endogenous reference to standardize microRNA expression levels. The results were expressed as relative expression levels after calibration with the universal reference data. P < 0.05.